Clinical pharmacology of vigabatrin - Wikidata - wikimedia - TriplyDB

Clinical pharmacology of vigabatrin

Clinical pharmacology of vigabatrin

http://www.wikidata.org/entity/Q38671473

about

Management of focal-onset seizures: an update on drug treatment.Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin.Effects of vigabatrin on partial seizures and cognitive function.Vigabatrin: a novel therapy for seizure disorders.Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study.Vigabatrin in the treatment of epilepsy in children Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting.Pharmacology of vigabatrin.Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy.Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.Vigabatrin for infantile spasms.Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin: focus on transporter interactions.The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy.New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin.Antiepileptic drugs in development: prospects for the near future.Advances in pharmacotherapy: recent developments in the treatment of epilepsy.Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug.Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs.Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs.Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms.Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures.Reduction of plasma alanine aminotransferase during vigabatrin treatment.Drugging the undruggable: gabapentin, pregabalin and the calcium channel α2δ subunit.Effect of vigabatrin and gabapentin on phynytoin pharmacokinetics in the dog.Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?

P2860

Q31061153-CB0AAA9F-2385-4423-A758-35BBA3C71F3A Q32066867-10D28C4A-688C-455C-8A26-E4F98FCB7410 Q33414470-83E359D2-1FA9-41E9-801B-A977564F67DA Q33733068-42199EB8-A921-42A1-8113-2E1241335604 Q33814543-E1F82D46-52A3-48D1-A9B8-3C507EF17103 Q33996679-343C65FE-1790-401E-A90F-D0DAE5748520 Q34059617-6545E222-2177-46B2-9102-AA745D369846 Q34396902-C7516DCF-9760-4BE9-877F-C57CCFBB7D86 Q34570859-85D203DD-D73C-4F97-8CF6-4952377A41D2 Q36223272-F3D0C200-DC21-4557-B2F1-8F75F1CE8F85 Q36627204-053D6C84-83FA-444F-BDDB-6E0C9799B479 Q37029357-95C7596F-0C1C-47B2-B9ED-112CD12C62FF Q37642768-6B34C237-1863-44B0-AD35-D9A25B412726 Q37808724-9C0FBAD8-8DAF-4417-B8C9-2B534B53213E Q37848404-8D0F6ADB-C270-46A0-B112-86A618A99D5D Q38261962-E9B02995-AE79-4996-AEEB-32C8B2C9F272 Q38621010-3F3902B4-33C3-4440-BEF3-AFED5BE03610 Q39477425-54F78648-0715-4654-9515-79D5E673F93C Q40570310-D9A073B0-0863-4364-984D-9D5AE28DEDB9 Q40748925-4B9CF075-5097-4DEF-A642-6A2C491528D8 Q40774655-E9CBD70B-51C0-4647-9223-9AD8DF7A8306 Q40924838-E132CC97-8C55-4B6D-8D05-FAED8BBCE86D Q40993447-518A03EA-B160-4310-BEAE-B6C9826CC2D7 Q41417980-9EC41B7A-9D9E-4A8A-8910-6A7BF538E857 Q42679724-E826CD64-43D4-4D47-8C0C-89FBBCAF1D5A Q48165148-F2C40017-D222-4206-8F45-5185D88B0FD7 Q51586661-101E63CE-B1D6-4A76-856C-DD4990C3FF20 Q53712744-923F7D4A-74F7-4B68-9F04-0314A7AB0167 Q53779452-4D5D2E2C-DC5B-46D0-8177-008D361AFF27 Q54231363-F7460A1F-2374-4AF5-B02A-0E37A41A9CB9

P2860

Clinical pharmacology of vigabatrin

http://www.wikidata.org/entity/Q38671473

description

1989 nî lūn-bûn

@nan

1989年の論文

@ja

1989年論文

@yue

1989年論文

@zh-hant

1989年論文

@zh-hk

1989年論文

@zh-mo

1989年論文

@zh-tw

1989年论文

@wuu

1989年论文

@zh

1989年论文

@zh-cn

name

Clinical pharmacology of vigabatrin

@en

type

label

Clinical pharmacology of vigabatrin

@en

prefLabel

Clinical pharmacology of vigabatrin

@en

P1433

Q38671473-7C792587-DBD9-4C5B-A509-C1F65044D9F6

P1476

Q38671473-BF642ED8-538B-4224-BE5E-E3FCCB712529

P2093

Q38671473-7EBBC6C8-FA8E-4298-ABBA-A361D210ED4B

P2860

Q38671473-0D70C9C8-E301-4699-8AF0-541CFE02F856

Q38671473-60FD5440-A6C4-4F74-B946-8FF2AAB94B58

Q38671473-63C98C3F-92F2-4BB2-8533-E53075DA5B11

Q38671473-7D72AAF3-BA76-45B6-9214-110063A706B3

Q38671473-88D82120-78A0-42C8-BB42-6A587936841F

Q38671473-BB2D108C-67FA-4175-A2FD-2D06EF3CF94D

Q38671473-F8BC1661-6612-490F-93F0-D26F8393B698

Q38671473-FFBAB36B-81E1-4434-A793-7834B409D1FA

P304

Q38671473-9319A893-88D3-427D-9B82-478079C33C2A

P31

Q38671473-E7D8E2DB-6830-43CA-8BF1-DCDD6CC0CB18

P356

Q38671473-EC8FFF6F-65C8-4440-9BD1-2A39DE21C950

P407

Q38671473-70F9D906-0E09-4659-9F0F-15997E8BC7E1

P478

Q38671473-575DDF2C-D200-4812-ACD9-DD5FB833A87F

P577

Q38671473-7115E21C-85EB-4608-9635-C5D821440DE3

P5875

Q38671473-26C1FCA4-FC33-4DB6-BE65-C538C63A5E4D

P698

Q38671473-70B61559-D9BB-4CFE-868E-C66733828FE8

P932

Q38671473-901663A3-7416-4FA8-BAA3-186CE7ACE425

P356

J.1365-2125.1989.TB03456.X

P1433

British Journal of Clinical Pharmacology

P1476

Clinical pharmacology of vigabatrin

@en

P2093

Schechter PJ

http://www.w3.org/2001/XMLSchema#string

P2860

4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain

The relationship between GABA concentrations in brain and cerebrospinal fluid.

Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurones and astrocytes.

Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors.

gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice.

Cerebrospinal fluid GABA as an index of brain GABA activity.

Concentration gradients of free and total gamma-aminobutyric acid and homocarnosine in human CSF: comparison of suboccipital and lumbar sampling.

Artifactual increases in the concentration of free GABA in samples of human cerebrospinal fluid are due to degradation of homocarnosine.

P304

19S-22S

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.1989.TB03456.X

http://www.w3.org/2001/XMLSchema#string

P407

P478

27 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

1989-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

20487836

http://www.w3.org/2001/XMLSchema#string

P698

2667604

http://www.w3.org/2001/XMLSchema#string

P932

1379674

http://www.w3.org/2001/XMLSchema#string